← Back to Search

Cancer Vaccine

ETBX-021 for Cancer

Phase 1
Waitlist Available
Research Sponsored by NantBioScience, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 year
Awards & highlights

Study Summary

The purpose of this study is to determine whether ETBX-021 is safe and effective in the treatment of unresectable locally advanced or metastatic HER2-low-expressing breast cancer.

Eligible Conditions
  • Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determination of maximum tolerated dose (MTD) or highest tested dose (HTD).
Number of subjects with clinically significant changes in laboratory values.
Occurrence of dose-limiting toxicities (DLTs).
+1 more
Secondary outcome measures
Disease control rate (DCR).
Duration of response.
Objective response rate (ORR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.
+2 more

Side effects data

From 2023 Phase 4 trial • 267 Patients • NCT05007041
13%
Upper Respiratory Infection
12%
COVID-19 Infection
1%
Chronic Obstructive Pulmonary Disease (COPD) exacerbation
1%
Hepatocellular Carcinoma
1%
Hospitalization for pacemaker due to arrhythmia
1%
Revision of right shoulder rotator cuff surgery
100%
80%
60%
40%
20%
0%
Study treatment Arm
Recombinant Zoster Vaccine (RZV) and Quadrivalent Adjuvanted Influenza Vaccine
Recombinant Zoster Vaccine (RZV) and High-Dose Quadrivalent Influenza Vaccine

Trial Design

1Treatment groups
Experimental Treatment
Group I: ETBX-021Experimental Treatment1 Intervention
Ad5 [E1-, E2b-]-HER2/neu Vaccine, Suspension for Injection

Find a Location

Who is running the clinical trial?

NantBioScience, Inc.Lead Sponsor
2 Previous Clinical Trials
16 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer
2016. "QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02751528.
All > Tb
~0 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top